One Cost Of Cancer: The Rising Price Of Treatment
Executive Summary
Given the debate surrounding the country's soaring health care costs, it's no surprise that cancer medicines - and their escalating prices - are coming under attack
You may also be interested in...
Finance Committee's Health Reform Vote Awaits New CBO Score
From the drug industry's point of view, the health care reform bill emerging from the Senate Finance Committee has few negative surprises
Genentech AVAiL Trial Results May Lower Avastin Dosing In NSCLC
Findings that a lower dose of Genentech's Avastin showed a similar treatment effect on progression-free survival as a higher dose in the AVAiL trial in first-line non-small cell lung cancer could impact physician prescribing patterns for the oncologic in lung cancer
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011